In a move to boost its natural killer candidates, Senti Bio will build out its own San Francisco manufacturing facility
Silicon Valley synthetic biology player and Roche collaborator Senti Bio has been hush-hush about much of its science since it was founded in 2016, but the company made noise Tuesday when it announced it signed a lease agreement to build out a commercial-scale manufacturing facility in Alameda, CA.
The 92,000 square-foot facility will be built with the goal of providing clinical- and commercial-scale manufacturing for off-the-shelf CAR natural killer cell candidates. The site will support clinical trials for SENTI-202 for acute myeloid leukemia and SENTI-301 for hepatocellular carcinoma. In-house manufacturing will help Senti maintain control over supply and quality, and is being designed to provide end-to-end manufacturing, as well as storage for the final product, the company said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.